Price movement over the last 24 hours
Aehr Test Systems vs Zoetis Inc — how do they compare? Aehr Test Systems trades at $67.9 (market cap $2.11B), while Zoetis Inc trades at $75.07 (market cap $31.62B). The key difference: Zoetis Inc is far larger — about 15× Aehr Test Systems's market cap, and Zoetis Inc pays a 2.81% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | ZTS | |
|---|---|---|
Market Cap | $2.11B | $31.62B |
Sector | Technology | Health |
52-Week High | $116.58 | $158.80 |
52-Week Low | $13.29 | $71.91 |
Enterprise Value | $2.08B | $38.92B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
Zoetis (ZTS) trades at $76.29, up 1.99% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite a consensus analyst price target of $101.43.
The stock presents a valuation opportunity with a P/E of 12.36 below industry averages, but faces near-term headwinds from legal challenges and mixed earnings performance. Upside potential exists if the company can overcome litigation concerns and return to consistent earnings beats, while downside risk persists from ongoing legal proceedings and competitive pressures in the animal health market.
Trailing returns across standard periods
Latest headlines on both assets
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →